Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. (October 2019)

• Record Type: Journal Article
• Authors: Narui, Kazutaka; Ishikawa, Takashi; Shimizu, Daisuke; Yamada, Akimitsu; Tanabe, Mikiko; Sasaki, Takeshi; Oba, Mari S.; Morita, Satoshi; Nawata, Shuichi; Kida, Kumiko; Mogaki, Masatoshi; Doi, Takako; Tsugawa, Koichiro; Ogata, Haruki; Ota, Tomohiko; Kosaka, Yoshimasa; Sengoku, Norihiko; Kuranami, Masaru; Niikura, Naoki; Saito, Yuki; Suzuki, Yasuhiro; Suto, Akihiko; Arioka, Hitoshi; Chishima, Takashi; Ichikawa, Yasushi; Endo, Itaru; Tokuda, Yutaka
• Is Part Of: Breast. Volume 47(2019)
• Page Start: 1
• Page End: 9
• Publication Date: 2019-10
• Subjects: Neo-adjuvant chemotherapy -- Breast cancer -- Anthracycline -- Taxane -- Basal -- Triple negative; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2019.06.003
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Background: It is important to determine whether anthracycline-containing regimens or taxane-containing regimens are more effective in individual patients. The present study compared the efficacy of six cycles of docetaxel and cyclophosphamide (TC6) with that of three cycles of 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel (FEC-D) in Japanese patients with hormone receptor (HR)-negative breast cancer (BC) to identify subtypes requiring anthracycline treatment. Methods: The study included 103 patients with operable HR-negative BC. Of these patients 53 received FEC-D and 50 received TC6. The primary endpoint was pathological complete response (pCR). The secondary endpoints were safety, breast-conserving surgery, disease-free survival (DFS) and overall survival (OS). The predictive factors for each regimen were evaluated. Results: Of the 103 patients, 97 completed the study (FEC-D, 50 patients; TC6, 47 patients). The pCR rate was higher with FEC-D (36%) than with TC6 (25.5%); however, the difference was not significant ( P = 0.265). TC6 was safer than FEC-D, as the adverse events with docetaxel in the FEC-D regimen were similar to those with the TC6 regimen. Among patients with basal BC, the pCR rate was significantly higher with FEC-D (42.9%) than with TC6 (13.6%; P = 0.033). Among patients with triple-negative breast cancer (TNBC), the DFS and OS were significantly better with FEC-D than with TC6 ( P = 0.016 and P = 0.034, respectively). Conclusion: TC6 was not as effective as FEC-D for treating HR-negative BC, as TC6 was not sufficient to treat TNBC, particularly the basal subtype. Our findings suggest that anthracyclines are better treatment options than taxanes for basal BC. Highlights: The pCR rate was higher with FEC-D than with TC6 ( P = 0.265). For basal BC, the pCR rate was higher with FEC-D than with TC6 ( P = 0.033). For TNBC, DFS and OS were better with FEC-D than with TC6 ( P = 0.016 and P = 0.034).